ROR2 was overexpressed in 56% of patient samples and the expression pattern of WNT5B expression is concurrent with that for ROR2. Knockdown of ROR2 suppressed proliferation and invasion of osteosarcoma cells, suggesting that ROR2 and WNT5B could be promising therapeutic targets for osteosarcoma patients (Morioka et al., 2009). The gene discussed is WNT5B; the disease is osteosarcoma.